23 January 2025
23 January 2025
The FDA reported that six patients died after being injected with Teva’s Copaxone or Sandoz’s Glatopa.
Tagrisso and Imfinzi are projected to generate global sales of $8bn and $7bn, respectively, by 2030, according to GlobalData.
The collaboration aims to prevent vision loss in BBS patients.
The collaboration will see Cellipont offering analytical method transfer and technology transfer.
The funding is provided by LifeArc, a medical research charity.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
